February 2026
M	T	W	T	F	S	S
	1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28

Andreas Tiede on Antithrombotic Drugs and Their Role in Cancer Progression and Metastasis

Andreas Tiede/ResearchGate

Dec 12, 2025, 05:31

Andreas Tiede on Antithrombotic Drugs and Their Role in Cancer Progression and Metastasis

Andreas Tiede, Professor, Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation at Hannover Medical School, shared a post by NEJM Group on LinkedIn, adding:

“I wouldn’t treat cancer patients with aspirin — yet —, but it is worthwhile observing the field of antithrombotic drugs affecting cancer progression and metastasis. Anticoagulants like heparin were sometimes reported to have similar effects.”

Quoting NEJM Group‘s post:

“A new study shows that aspirin enhances antimetastatic immunity by decreasing platelet activation, thereby releasing T cells from suppression by thromboxane A2.

The effects of aspirin on cancer metastasis were first recognized more than 50 years ago. In a seminal study, Gasic and colleagues found that fewer lung metastases developed in mice whose drinking water was supplemented with aspirin than in control mice.

Epidemiologic data support the hypothesis that aspirin prevents cancer, but the design and interpretation of randomized trials have been hampered by a lack of mechanistic understanding.

This is changing. In a recent report, Yang and colleagues describe a previously unrecognized immunosuppressive mechanism that prevents T cells from eliminating cancer metastases.

At the heart of this prometastatic mechanism is a protein called ARHGEF1, which is activated by thromboxane A2 (TXA2), a metabolite of the platelet arachidonic acid pathway. This pathway is inhibited by aspirin through inactivation of cyclooxygenase (COX) enzymes.

Title: Understanding How Aspirin Prevents Metastasis

Authors: Ruth E. Langley, John Burn

Andreas Tiede on Antithrombotic Drugs and Their Role in Cancer Progression and Metastasis